Novel cancer immunotherapeutic agent targeting tumor and tumor immune microenvironment for the treatment of triple negative breast cancer
Technology Introduction:
Technology Introduction:This invention describes the discovery and development of BPR5K230, a potent, orally bioavailable AXL and MERTK selective kinase inhibitor targeting tumor and tumor immune microenvironment for the treatment of triple negative breast cancer patients who fail current therapies and whose tumors and immune cells overexpress AXL and MERTK. The current invention represents a novel target-driven, patient-stratified precision cancer medicine for tough-to-treat cancers.
Industrial Applications:
-
National Health Research Institutes
National Health Research Institutes (NHRI) is a medical and health research organization in Taiwan, established as a public-funded foundation. Its main research areas include medicine, pharmaceuticals, public health, and other life sciences, as well as related technologies such as vaccine development.
